The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
Open accessAbstract
BACKGROUND: Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis. METHODS: We conducted a 12-week, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of 0.5 mg per kilogram of body weight) administered subcutaneously at baseline, week 4, and week 8, as compared with placebo, in patients with moderate-to-severe prurigo nodularis and severe pruritus. Moderate-to-severe prurigo nodularis was defined as 20 or more nodules, and severe pruritus was defined as a mean score of at least 7 for the worst daily intensity of pruritus on the numerical rating scale (scores range from 0 [no itch] to 10 [worst itch imaginable]). The primary outcome was the percent change from baseline in the mean peak score for pruritus on the numerical rating scale at week 4. Secondary outcomes included additional measures of itching and disease severity. Safety assessments were performed through week 18. RESULTS: A total of 70 patients were randomly assigned in a 1:1 ratio to receive nemolizumab (34 patients) or placebo (36). The initial pruritus score on the numerical rating scale was 8.4 in each group. At week 4, the peak pruritus score on the numerical rating scale was reduced from baseline by 4.5 points (change, -53.0%) in the nemolizumab group, as compared with a reduction of 1.7 points (change, -20.2%) in the placebo group (difference, -32.8 percentage points; 95% confidence interval, -46.8 to -18.8; P<0.001). Results for secondary outcomes were in the same direction as for the primary outcome. Nemolizumab was associated with gastrointestinal symptoms (abdominal pain and diarrhea) and musculoskeletal symptoms. CONCLUSIONS: Nemolizumab resulted in a greater reduction in pruritus and severity of skin lesions than placebo in patients with prurigo nodularis but was associated with adverse events. Larger and longer trials are needed to determine the durability and safety of nemolizumab for the treatment of prurigo nodularis. (Funded by Galderma; ClinicalTrials.gov number, NCT03181503.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, nemolizumab generated promising results in prurigo nodularis, a highly pruritic skin disorder assumed to be related to AD193.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [193]
In the citing paper
“However, this conclusion may not be generalized for a number of itchy skin disorders such as prurigo nodularis in which targeting itch remains promising193,205,210–212.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [193]
Citations
Cites
IL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Muller, A., Lauerma, A. I., Pivarcsi, A., Soto, H., Kemeny, L., Alenius, H., Dieu-Nosjean, M.-C., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,005
Pereira, M. P., Steinke, S., Zeidler, C., Forner, C., Riepe, C., Augustin, M., Bobko, S., Dalgard, F., Elberling, J., Garcovich, S., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14570 · Cited by 274
Self-citationEthnic differences and comorbidities of 909 prurigo nodularis patients
Boozalis, E., Tang, O., Patel, S., Semenov, Y. R., Pereira, M. P., Stander, S., Kang, S., & Kwatra, S. G. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.047 · Cited by 189
Self-citationIL-31: A new key player in dermatology and beyond
Bağci, I. S., & Ruzicka, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.10.045 · Cited by 160
Chronic Prurigo of Nodular Type: A Review
Zeidler, C., Tsianakas, A., Pereira, M. P., Ständer, H. F., Yosipovitch, G., & Ständer, S. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2774 · Cited by 126
Self-citationPrurigo Nodularis and Its Management
Zeidler, C., Yosipovitch, G., & Ständer, S. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.003 · Cited by 112
Self-citationSteinke, S., Zeidler, C., Riepe, C., Bruland, P., Soto‐Rey, I., Storck, M., Augustin, M., Ивановна, Б. С., Garcovich, S., Legat, F. J., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.044 · Cited by 104
Self-citationItch in dermatomyositis: the role of increased skin interleukin-31
Kim, H. J., Zeidi, M., Bonciani, D., Pena, S. M., Tiao, J., Sahu, S., & Werth, V. P. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16498 · Cited by 94
The pathogenesis of Prurigo nodularis – ‘Super‐Itch’ in exploration
Zeidler, C., & Ständer, S. (2016) · European Journal of Pain · doi:10.1002/ejp.767 · Cited by 91
Self-citationBrenaut, E., Halvorsen, J. A., Dalgard, F. J., Lien, L., Balieva, F., Sampogna, F., Linder, D., Evers, A. W. M., Jemec, G. B. E., Gieler, U., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15145 · Cited by 85
Self-citation
Cited by
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Self-citationWollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
Self-citationA basophil-neuronal axis promotes itch
Wang, F., Trier, A. M., Li, F., Kim, S., Chen, Z., Chai, J. N., Mack, M. R., Morrison, S. A., Hamilton, J. D., Baek, J., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.033 · Cited by 264
Interleukin‐31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M., & Buddenkotte, J. (2021) · Allergy · doi:10.1111/all.14791 · Cited by 228
Self-citationPhase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
Kwatra, S. G., Yosipovitch, G., Legat, F. J., Reich, A., Paul, C., Simon, D., Naldi, L., Lynde, C., De Bruin-Weller, M. S., Nahm, W. K., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301333 · Cited by 193
Self-citation
Metadata
- Authors
- Ständer, S., Yosipovitch, G., Legat, F. J., Lacour, J.-P., Paul, C., Narbutt, J., Bieber, T., Misery, L., Wollenberg, A., Reich, A., Ahmad, F., & Piketty, C.
- Affiliations
- University Hospital Bonn (DE)
- University of Graz (AT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-20
- Volume
- 382
- Issue
- 8
- Pages
- 706-716
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3008008049
- Cited by
- 281
- References
- 18
- Citations by year
- 2026: 22 · 2025: 36 · 2024: 39 · 2023: 63 · 2022: 40 · 2021: 52 · 2020: 28
- FWCI
- 33.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nestle Skin Health
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
- Keywords
- prurigo nodularis, nemolizumab, monoclonal antibodies, pruritus, skin lesions, adverse events, gastrointestinal symptoms, musculoskeletal symptoms, treatment safety, treatment efficacy, numerical rating scale
- MeSH terms
- Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Injections, Subcutaneous, Male, Middle Aged, Muscular Diseases, Prurigo, Pruritus, Young Adult, Antibodies, Monoclonal, Humanized, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. https://app.cochat.ai/papers/10.1056/nejmoa1908316
- The paper
- Ständer, S., Yosipovitch, G., Legat, F. J., Lacour, J.-P., Paul, C., Narbutt, J., Bieber, T., Misery, L., Wollenberg, A., Reich, A., Ahmad, F., & Piketty, C. (2020). Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1908316
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.